Fresenius Kabi sells cancer compounding business to NewCo Pharma


Will focus on compounding for parenteral nutrition products in Germany going forward

Healthcare company Fresenius Kabi has sold its German subsidiary CFL to NewCo Pharma, a compounding company based in Mannheim, for an undisclosed sum.

Both companies specialise in IV oncology drug compounding.

CFL has compounding centres in Aschaffenberg and Munich as well as compounding pharmacies in Bonn (Compounding Rheinische), Mannheim (Fortune Manufacturing), Osnabruck (Onco Service) and Stuttgart (cas central compounding Baden-Wuerttemberg).

In 2014, CFL had sales of €77m.

Sign up for your free email newsletter

Fresenius Kabi says it will remain active in compounding. In Germany, it will focus on parenteral nutrition products, an area that the company says 'offers attractive growth opportunities'.